185 related articles for article (PubMed ID: 11939727)
1. WT1 immunoreactivity in uterine papillary serous carcinomas is different from ovarian serous carcinomas.
Goldstein NS; Uzieblo A
Am J Clin Pathol; 2002 Apr; 117(4):541-5. PubMed ID: 11939727
[TBL] [Abstract][Full Text] [Related]
2. Differential expression of WT-1 in serous carcinomas in the peritoneum with or without associated serous carcinoma in endometrial polyps.
Euscher ED; Malpica A; Deavers MT; Silva EG
Am J Surg Pathol; 2005 Aug; 29(8):1074-8. PubMed ID: 16006803
[TBL] [Abstract][Full Text] [Related]
3. An immunohistochemical comparison between low-grade and high-grade ovarian serous carcinomas: significantly higher expression of p53, MIB1, BCL2, HER-2/neu, and C-KIT in high-grade neoplasms.
O'Neill CJ; Deavers MT; Malpica A; Foster H; McCluggage WG
Am J Surg Pathol; 2005 Aug; 29(8):1034-41. PubMed ID: 16006797
[TBL] [Abstract][Full Text] [Related]
4. Serous papillary adenocarcinoma of the female genital organs and invasive micropapillary carcinoma of the breast. Are WT1, CA125, and GCDFP-15 useful in differential diagnosis?
Moritani S; Ichihara S; Hasegawa M; Endo T; Oiwa M; Yoshikawa K; Sato Y; Aoyama H; Hayashi T; Kushima R
Hum Pathol; 2008 May; 39(5):666-71. PubMed ID: 18339419
[TBL] [Abstract][Full Text] [Related]
5. WT1 is an integral component of an antibody panel to distinguish pancreaticobiliary and some ovarian epithelial neoplasms.
Goldstein NS; Bassi D; Uzieblo A
Am J Clin Pathol; 2001 Aug; 116(2):246-52. PubMed ID: 11488072
[TBL] [Abstract][Full Text] [Related]
6. Overexpression of kallikrein 10 (hK10) in uterine serous papillary carcinomas.
Santin AD; Diamandis EP; Bellone S; Marizzoni M; Bandiera E; Palmieri M; Papasakelariou C; Katsaros D; Burnett A; Pecorelli S
Am J Obstet Gynecol; 2006 May; 194(5):1296-302. PubMed ID: 16647913
[TBL] [Abstract][Full Text] [Related]
7. Genetic alterations of the WT1 gene in papillary serous carcinoma of the peritoneum.
Schorge JO; Miller YB; Qi LJ; Muto MG; Welch WR; Berkowitz RS; Mok SC
Gynecol Oncol; 2000 Mar; 76(3):369-72. PubMed ID: 10684712
[TBL] [Abstract][Full Text] [Related]
8. [Clinicopathologic analysis and expression of cyclin D1 and p53 of ovarian borderline tumors and carcinomas].
Shao HL; Shen DH; Xue WC; Li Y; Yu YZ
Zhonghua Fu Chan Ke Za Zhi; 2007 Apr; 42(4):227-32. PubMed ID: 17631760
[TBL] [Abstract][Full Text] [Related]
9. Wilms tumor gene immunoreactivity in primary serous carcinomas of the fallopian tube, ovary, endometrium, and peritoneum.
Hashi A; Yuminamochi T; Murata S; Iwamoto H; Honda T; Hoshi K
Int J Gynecol Pathol; 2003 Oct; 22(4):374-7. PubMed ID: 14501819
[TBL] [Abstract][Full Text] [Related]
10. Biomarker expression in pelvic high-grade serous carcinoma: comparison of ovarian and omental sites.
Köbel M; Turbin D; Kalloger SE; Gao D; Huntsman DG; Gilks CB
Int J Gynecol Pathol; 2011 Jul; 30(4):366-71. PubMed ID: 21623201
[TBL] [Abstract][Full Text] [Related]
11. Diagnostic utility of WT1 immunostaining in ovarian sertoli cell tumor.
Zhao C; Bratthauer GL; Barner R; Vang R
Am J Surg Pathol; 2007 Sep; 31(9):1378-86. PubMed ID: 17721194
[TBL] [Abstract][Full Text] [Related]
12. WT1 and WT1-AS genes are inactivated by promoter methylation in ovarian clear cell adenocarcinoma.
Kaneuchi M; Sasaki M; Tanaka Y; Shiina H; Yamada H; Yamamoto R; Sakuragi N; Enokida H; Verma M; Dahiya R
Cancer; 2005 Nov; 104(9):1924-30. PubMed ID: 16134181
[TBL] [Abstract][Full Text] [Related]
13. The utility of calretinin, inhibin, and WT1 immunohistochemical staining in the differential diagnosis of ovarian tumors.
Cathro HP; Stoler MH
Hum Pathol; 2005 Feb; 36(2):195-201. PubMed ID: 15754297
[TBL] [Abstract][Full Text] [Related]
14. Wilms Tumor Gene (WT1) and p53 expression in endometrial carcinomas: a study of 130 cases using a tissue microarray.
Dupont J; Wang X; Marshall DS; Leitao M; Hedvat CV; Hummer A; Thaler H; O'Reilly RJ; Soslow RA
Gynecol Oncol; 2004 Aug; 94(2):449-55. PubMed ID: 15297187
[TBL] [Abstract][Full Text] [Related]
15. An immunohistochemical panel to distinguish ovarian from uterine serous papillary carcinomas.
Zhang Y; Garcia-Buitrago MT; Koru-Sengul T; Schuman S; Ganjei-Azar P
Int J Gynecol Pathol; 2013 Sep; 32(5):476-81. PubMed ID: 23896709
[TBL] [Abstract][Full Text] [Related]
16. Differential expression of WT1 and p53 in serous and endometrioid carcinomas of the endometrium.
Egan JA; Ionescu MC; Eapen E; Jones JG; Marshall DS
Int J Gynecol Pathol; 2004 Apr; 23(2):119-22. PubMed ID: 15084839
[TBL] [Abstract][Full Text] [Related]
17. Expression level of Wilms tumor 1 (WT1) protein has limited prognostic value in epithelial ovarian cancer: from the Danish "MALOVA" ovarian cancer study.
Høgdall EV; Christensen L; Kjaer SK; Blaakaer J; Christensen IJ; Gayther S; Jacobs IJ; Høgdall CK
Gynecol Oncol; 2007 Aug; 106(2):318-24. PubMed ID: 17540436
[TBL] [Abstract][Full Text] [Related]
18. Poly(adenosine diphosphate-ribose) polymerase expression in serous ovarian carcinoma: correlation with p53, MIB-1, and outcome.
Brustmann H
Int J Gynecol Pathol; 2007 Apr; 26(2):147-53. PubMed ID: 17413981
[TBL] [Abstract][Full Text] [Related]
19. High-grade Endometrioid Carcinoma of the Ovary: A Clinicopathologic Study of 30 Cases.
Assem H; Rambau PF; Lee S; Ogilvie T; Sienko A; Kelemen LE; Köbel M
Am J Surg Pathol; 2018 Apr; 42(4):534-544. PubMed ID: 29309296
[TBL] [Abstract][Full Text] [Related]
20. Immunohistochemical overexpression of p16 and p53 in uterine serous carcinoma and ovarian high-grade serous carcinoma.
Chiesa-Vottero AG; Malpica A; Deavers MT; Broaddus R; Nuovo GJ; Silva EG
Int J Gynecol Pathol; 2007 Jul; 26(3):328-33. PubMed ID: 17581420
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
